Fox Chase Cancer Center, part of Temple University Health System, is celebrating 50 years as one of the elite National Cancer Institute-designated comprehensive cancer centers, a designation it has held since 1974 for its excellence in cancer research, prevention and clinical services. Renowned for breakthroughs in cancer genetics, Fox Chase also pioneered treatments like the NanoKnife System for prostate cancer, which offers a less invasive alternative to surgery. The center’s commitment to innovation is evident through its research portfolio, which garnered over $76 million in 2023. With cutting-edge programs in urologic oncology, adaptive radiation therapy and clinical trials, Fox Chase remains a leader in personalized cancer care. Its scientists, honored with numerous prestigious awards including two Nobel Prizes, continue to publish influential research and drive advancements in cancer treatment.
